FrancophonIA/ELRC3.0 huggingface dataset:
English: Warnings and precautions Talk to your doctor before taking Tolucombi if you are suffering or have ever suffered from any of the following conditions or illnesses: - Low blood pressure (hypotension), likely to occur if you are dehydrated (excessive loss of body water) or have salt deficiency due to diuretic therapy (water tablets), low-salt diet, diarrhoea, vomiting, or haemodialysis.
Slovenian: Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila Tolucombi obvestite svojega zdravnika, če imate ali ste kadar koli imeli katero koli od naslednjih bolezenskih stanj ali bolezni: - nizek krvni tlak (hipotenzijo), ki se pojavi, če ste dehidrirani (prevelika izguba vode iz telesa) ali imate pomanjkanje soli zaradi diuretičnega zdravljenja (tablet za odvajanje vode), diete z majhno vsebnostjo soli, driske, ste bruhali ali imeli hemodializo, - ledvično bolezen ali presajeno ledvico, - stenozo ledvične arterije (zožitev krvnih žil v eni ali obeh ledvicah), - jetrno bolezen, - težave s srcem, - sladkorno bolezen, - protin, - zvišano raven aldosterona (zadrževanje vode in soli v telesu ter neravnovesje različnih mineralov v krvi), - sistemski eritematozni lupus (poimenovan tudi ''lupus'' ali ''SLE''), bolezen, pri kateri telesni imunski sistem napade telo, - učinkovina hidroklorotiazid lahko povzroči neobičajno reakcijo, katere posledica sta poslabšan vid in očesna bolečina.
English: Neoplasms benign, malignant and unspecified (incl cysts and polyps) Not known: Non-melanoma skin cancer (Basal cell carcinoma and Squamous cell carcinoma)
Slovenian: Nemelanomski kožni rak (bazalnocelični karcinom in ploščatocelični karcinom)
English: Psychiatric disorders Uncommon: Anxiety Rare:
Slovenian: Psihiatrične motnje Neznana:
English: White to almost white or pinkish white on one side and pink marbled on the opposite side of two-layer biconvex oval tablet, tablet dimensions 15 mm x 7 mm.
Slovenian: Dvoslojne, izbočene, ovalne tablete, bele do skoraj bele ali rožnato-bele barve na eni strani in roza marmorirane na drugi strani, velikosti 15 mm x 7 mm.
English: - Refractory hypokalaemia, hypercalcaemia.
Slovenian: - Hiponatriemija in hipokloremična alkaloza
English: Dizziness or drowsiness may occasionally occur when taking Tolucombi.
Slovenian: Zdravilo Tolucombi lahko včasih povzroči omotico ali dremavost.
English: Hypercalcaemia
Slovenian: hiperkaliemija
English: Protect your skin from sun exposure and UV rays while taking Tolucombi.
Slovenian: Med zdravila Tolucombi zaščitite kožo pred izpostavljenostjo soncu in UV-žarkom.
English: Tolucombi 80 mg/12.5 mg tablets telmisartan/hydrochlorothiazide
Slovenian: Tolucombi 80 mg/12,5 mg tablete telmisartan/hidroklorotiazid
English: Acute Myopia and Angle-Closure Glaucoma
Slovenian: Akutna miopija in glavkom zaprtega zakotja
English: Vascular disorders Not known: Vasculitis necrotizing
Slovenian: nekrotizirajoči vaskulitis
English: White to almost white or pinkish white on one side and pink marbled on the opposite side of two-layer biconvex oval tablet, tablet dimensions 18 mm x 9 mm.
Slovenian: Dvoslojne, izbočene, ovalne tablete, bele do skoraj bele ali rožnato-bele barve na eni strani in roza marmorirane na drugi strani, velikosti 18 mm x 9 mm.
English: Renal and urinary disorders Not known: Nephritis interstitial, renal dysfunction, glycosuria
Slovenian: intersticijski nefritis, motnje ledvičnega delovanja, glikozurija
English: General disorders and administration site conditions Not known: Pyrexia
Slovenian: Splošne težave in spremembe na mestu aplikacije Neznana:
English: Tolucombi 40 mg/12.5 mg tablets:
Slovenian: Tolucombi 40 mg/12,5 mg tablete
English: White to yellowish white on one side and yellow marbled on the opposite side of two-layer biconvex oval tablet, tablet dimensions 18 mm x 9 mm.
Slovenian: Dvoslojne, izbočene, ovalne tablete, bele do rumenkasto bele barve na eni strani in rumeno marmorirane na drugi strani, velikosti 18 mm x 9 mm.
English: Uncommon: Upper respiratory tract infection, urinary tract infection including cystitis Rare:
Slovenian: okužba zgornjih dihal, okužba sečil, tudi cistitis
English: Endocrine disorders Not known: Diabetes mellitus inadequate control
Slovenian: Bolezni endokrinega sistema Neznana:
English: Respiratory, thoracic and mediastinal disorders Uncommon: Cough
Slovenian: Bolezni jeter, žolčnika in žolčevodov Neznana:
English: Metabolism and nutrition disorders Uncommon: Hyperkalaemia Rare:
Slovenian: Zelo redki: hipokloremična alkaloza Neznana:
English: Hypomagnesaemia
Slovenian: hipomagneziemija
English: - Hypomagnesaemia
Slovenian: - Hipomagneziemija
English: Infections and infestations Not known: Sialadenitis
Slovenian: Infekcijske in parazitske bolezni Neznana:
English: Tolucombi is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.
Slovenian: Zdravila Tolucombi ne priporočajo materam, ki dojijo.
English: Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function.
Slovenian: Pri bolnikih z zmanjšanim ledvičnim delovanjem se lahko pojavi azotemija, ki jo povzročajo tiazidni diuretiki.
English: Hepatobiliary disorders Not known: Jaundice hepatocellular, jaundice cholestatic
Slovenian: hepatocelularna zlatenica, holestatska zlatenica
English: Lithium
Slovenian: omotica
English: Arthrosis, tendon pain
Slovenian: tahikardija, aritmije
English: Nausea Not known: Pancreatitis, stomach discomfort
Slovenian: pankreatitis, želodčne težave
English: Ref.: EMEA/CHMP/746208/2009
Slovenian: : EMEA/CHMP/78791/2010
English: The study also looked at how long the patients survived.
Slovenian: Študija je proučevala tudi čas preživetja bolnikov.
English: Avastin has been authorised since January 2005.
Slovenian: Zdravilo Avastin je bilo odobreno januarja 2005.
English: International non-proprietary name (INN): bevacizumab
Slovenian: Mednarodno nelastniško ime (INN): bevacizumab
English: The company presented the results of one main study involving 167 patients with glioblastoma that had come back after one or two previous courses of treatment.
Slovenian: Družba je predstavila rezultate ene glavne študije, v kateri je bilo vključenih 167 bolnikov z glioblastomom, ki se je ponovil po enem ali dveh predhodnih zdravljenjih.
English: The company that applied for the change to the authorisation is Roche Registration Limited.
Slovenian: Družba, ki je zaprosila za spremembo dovoljenja za promet, je Roche Registration Limited.
English: Questions and answers on the recommendation for the refusal of a change to the marketing authorisation for Avastin
Slovenian: Vprašanja in odgovori v zvezi s priporočilom za zavrnitev vloge za spremembo dovoljenja za promet z zdravilom Avastin
English: There were two main measures of effectiveness: the number of patients whose tumours had responded to treatment ; and ‘progressionfree survival' (the number of patients who were still alive and whose disease had not got worse) after six months of treatment.
Slovenian: Glavni merili učinkovitosti sta bili število bolnikov, pri katerih so se tumorji odzvali na zdravljenje, in „čas preživetja brez napredovanja bolezni“ (število bolnikov, ki so bili še živi in pri katerih se diagnoza ni poslabšala) po šestih mesecih zdravljenja.
English: The full European Public Assessment Report for Avastin is available here.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Avastin je na voljo tukaj.
English: It was to be used when the disease had relapsed (come back after previous treatment).
Slovenian: Uporabljalo naj bi se pri relapsu bolezni (ponovitvi po predhodnem zdravljenju).
English: The CHMP was concerned that the company had not provided sufficient evidence of the medicine's benefits, because the number of patients who responded to treatment was not dramatic and because response rates may not be a suitable measure of the medicine's effectiveness.
Slovenian: CHMP je bil zaskrbljen, da družba ni predložila zadostnih dokazov o koristi zdravila, saj število bolnikov, ki so se odzvali na zdravljenje, ni bilo dramatično, in ker stopnja odziva bolnikov morda ni primerno merilo za učinkovitost zdravila.
English: There are no consequences on the use of Avastin in its authorised indications, for which the balance of benefits and risks remains unchanged.
Slovenian: Umik nima nobenih posledic za uporabo zdravila Avastin za odobrene indikacije, pri katerih ostaja razmerje med koristmi in tveganji nespremenjeno.
English: Half of the patients received Avastin alone and the other half received Avastin together with irinotecan.
Slovenian: Polovica bolnikov je prejemala zdravilo Avastin samostojno, druga polovica pa v kombinaciji z irinotekanom.
English: Glioblastoma is a type of brain tumour that affects the ‘glial' cells (the cells that surround and support the nerve cells).
Slovenian: Glioblastom je vrsta možganskega tumorja, ki vpliva na nevroglijske celice (celice, ki obkrožajo in podpirajo živčne celice).
English: As a result, the cancer cells cannot develop their own blood supply and are starved of oxygen and nutrients, helping to slow down the growth of tumours.
Slovenian: Zaradi tega se rakave celice ne morejo oskrbovati s krvjo ter dobivajo premalo kisika in hranil, to pa pripomore k upočasnjeni rasti tumorjev.
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and attach to a specific structure (called an antigen) that is found in the body.
Slovenian: Monoklonsko protitelo je protitelo (vrsta beljakovine), ki je bilo zasnovano tako, da prepozna posebno strukturo (imenovano antigen), ki se nahaja v telesu, in se veže nanjo.
English: What are the consequences of the refusal for patients in clinical trials using Avastin?
Slovenian: Kakšne so posledice zavrnitve za bolnike, ki sodelujejo v kliničnih preskušanjih zdravila Avastin?
English: Bevacizumab has been designed to attach to vascular endothelial growth factor (VEGF), a protein that circulates in the blood and makes blood vessels grow.
Slovenian: Bevacizumab je bil zasnovan tako, da se veže na endotelijski rastni faktor v žilah (VEGF), beljakovino, ki kroži po krvi in omogoča rast krvnih žil.
English: The active substance in Avastin, bevacizumab, is a monoclonal antibody.
Slovenian: Zdravilna učinkovina v zdravilu Avastin, bevacizumab, je monoklonsko protitelo.
English: On 19 November 2009, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of a change to the marketing authorisation for the medicinal product Avastin.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) je v svojem negativnem mnenju z dne 19. novembra 2009 priporočil zavrnitev vloge za spremembo dovoljenja za promet z zdravilom Avastin.
English: The change concerned an extension of indication to add the treatment of glioblastoma after relapse.
Slovenian: Sprememba se je nanašala na razširitev indikacije z vključitvijo zdravljenja glioblastomov po ponovitvi bolezni.
English: Avastin was also expected to be used to treat another type of cancer called glioblastoma.
Slovenian: Zdravilo Avastin naj bi se uporabljalo tudi za zdravljenje druge vrste raka, imenovane glioblastom.
English: In addition, the CHMP could not interpret the findings on survival because the study did not compare Avastin directly with any other treatments.
Slovenian: Poleg tega si CHMP ni mogel razlagati ugotovitev glede preživetja, saj družba zdravila Avastin ni neposredno primerjala z drugimi zdravili.
English: Avastin was to be used in on its own or in combination with irinotecan (another anticancer medicine).
Slovenian: Zdravilo Avastin naj bi se uporabljalo samostojno ali v kombinaciji z irinotekanom (drugim zdravilom proti raku).
English: By attaching to VEGF, Avastin stops it having an effect.
Slovenian: Z vezavo na VEGF zdravilo Avastin zaustavi njegovo delovanje.
English: It is already used in combination with other medicines to treat cancer of the colon or rectum (large intestine), breast cancer, non-small cell lung cancer and kidney cancer.
Slovenian: Uporablja se v kombinaciji z drugimi zdravili za zdravljenje raka kolona ali danke (debelega črevesa), raka dojke, nedrobnoceličnega pljučnega raka in raka ledvic.
English: What is happening with Avastin for the treatment of colorectal, breast, lung and kidney cancer?
Slovenian: Kaj se dogaja z zdravilom Avastin za zdravljenje kolorektalnega raka, raka dojke, pljučnega raka in raka ledvic?
English: The company informed the CHMP that there are no consequences for patients currently included in clinical trials with Avastin for glioblastoma.
Slovenian: Družba je obvestila CHMP, da umik nima nobenih posledic za bolnike, ki trenutno sodelujejo v kliničnih preskušanjih zdravila Avastin za glioblastom.
English: In glioblastoma, Avastin is expected to work in the same way as it does in its existing indications.
Slovenian: Zdravilo Avastin naj bi pri glioblastomu delovalo na enak način kot pri drugih odobrenih indikacijah.
English: Therefore, at that point in time, the CHMP was of the opinion that the balance of benefits and risks of Avastin in the treatment of glioblastoma after relapse could not be established.
Slovenian: Zato je CHMP tokrat menil, da ni mogoče ugotoviti ravnotežja med koristmi in tveganji zdravila Avastin pri zdravljenju glioblastoma po ponovitvi.
English: Avastin is a concentrate that is made up into a solution for infusion (drip into a vein).
Slovenian: Zdravilo Avastin je koncentrat za pripravo raztopine za infundiranje (kapalne infuzije v veno).
English: It contains the active substance bevacizumab.
Slovenian: Vsebuje zdravilno učinkovino bevacizumab.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Lixiana on 19 June 2015.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Lixiana, veljavno po vsej Evropski uniji, izdala 19. junija 2015.
English: The full EPAR for Lixiana can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Lixiana je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: What measures are being taken to ensure the safe and effective use of Lixiana?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Lixiana?
English: This is a summary of the European public assessment report (EPAR) for Lixiana.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Lixiana.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Lixiana's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Lixiana večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: Lixiana is available as tablets (15, 30 and 60 mg) and can only be obtained with a prescription.
Slovenian: Zdravilo Lixiana je na voljo v obliki tablet (15, 30 in 60 mg), njegovo predpisovanje in izdaja pa je le na recept.
English: Although there was greater a risk of bleeding from the mucosa (tissues lining body cavities such as the nose, gut and vagina), the Committee considered that the risk could be managed with appropriate measures.
Slovenian: Čeprav so opazili večje tveganje krvavitve iz sluznice (tkiv, ki obdajajo telesne odprtine, kot so nos, črevo in nožnica), je odbor menil, da je tveganje mogoče obvladati z ustreznimi ukrepi.
English: It is used in patients who have one or more risk factors, such as having had a previous stroke, high blood pressure, diabetes, heart failure or being 75 years old or over;
Slovenian: Uporablja se pri bolnikih z enim ali več dejavniki tveganja, kot so možganska kap v preteklosti, visok krvni tlak, sladkorna bolezen, srčno popuščanje ali starost nad 75 let;
English: With respect to safety, overall the risk of serious bleeding such as bleeding into the brain was reduced compared with warfarin, although there may be less difference where warfarin treatment is well managed.
Slovenian: Kar zadeva varnost, je bilo splošno tveganje za resno krvavitev, kot je denimo krvavitev v možganih, manjše kot pri uporabi varfarina, čeprav so lahko razlike manjše, kadar je zdravljenje z varfarinom dobro vodeno.
English: It must also not be used in pregnant or breastfeeding women or in patients also being treated with another anticoagulant.
Slovenian: Prav tako se ne sme uporabljati pri nosečnicah in doječih materah ter pri bolnikih, ki se že zdravijo z drugim antikoagulantom.
English: Lixiana is an anticoagulant medicine (a medicine that prevents blood clotting) used in adults:
Slovenian: Zdravilo Lixiana je antikoagulant (zdravilo za preprečevanje strjevanja krvi), ki se uporablja pri odraslih:
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Lixiana have also been included in the summary of product characteristics and the package leaflet.Other information about Lixiana
Slovenian: Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Lixiana upoštevati zdravstveni delavci in bolniki, so vključeni tudi v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo.Druge informacije o zdravilu Lixiana
English: What benefits of Lixiana have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Lixiana izkazalo v študijah?
English: The company that markets Lixiana will provide educational materials for doctors prescribing the medicine and an alert card for patients, explaining the risks of bleeding with the medicine and how to manage them.
Slovenian: Družba, ki trži zdravilo Lixiana, bo zagotovila izobraževalno gradivo za zdravnike, ki bodo predpisovali zdravilo, in opozorilno kartico za bolnike, na kateri bodo pojasnjena tveganja krvavitve pri uporabi zdravila in navodila za njihovo obvladovanje.
English: What is Lixiana and what is it used for?
Slovenian: Kaj je zdravilo Lixiana in za kaj se uporablja?
English: Lixiana must not be used in patients who are actively bleeding, have liver diseases that affect blood clotting, have severe uncontrolled high blood pressure or who have a condition putting them at significant risk of major bleeding.
Slovenian: Zdravilo Lixiana se ne sme uporabljati pri bolnikih z aktivno krvavitvijo, boleznijo jeter, ki vpliva na strjevanje krvi, nenadzorovanim zelo visokim krvnim tlakom ali boleznijo, zaradi katere pri njih obstaja veliko tveganje za hude krvavitve.
English: For more information about treatment with Lixiana, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Lixiana preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: What are the risks associated with Lixiana?
Slovenian: Kakšna tveganja so povezana z zdravilom Lixiana?
English: The most common side effects with Lixiana (which may affect up to 1 in 10 people) are bleeding from skin and soft tissues, nose bleeds (epistaxis) and the vagina.
Slovenian: Najpogostejši neželeni učinki zdravila Lixiana (ki lahko prizadenejo največ 1 osebo od 10) so krvavitev iz kože in mehkih tkiv ter krvavitve iz nosu (epistaksa) in nožnice.
English: Other common side effects are anaemia (low levels of red blood cells), rash, itching, headache, dizziness, belly pain and abnormal results in tests of liver function.
Slovenian: Drugi pogosti neželeni učinki so anemija (nizke ravni rdečih krvnih celic), izpuščaji, srbenje, glavobol, omotica, bolečine v trebuhu in nenormalni izvidi preiskav delovanja jeter.
English: Why is Lixiana approved?
Slovenian: Zakaj je bilo zdravilo Lixiana odobreno?
English: When another recommended definition of the type of stroke was used, embolism or stroke due to blood clots was seen in 143 patients given Lixiana (0.9%) and 157 given warfarin (1%).
Slovenian: Ko so uporabili drugo priporočeno opredelitev vrste možganske kapi, so embolijo ali možgansko kap zaradi krvnih strdkov zabeležili pri 143 bolnikih, ki so prejemali zdravilo Lixiana (0,9 %), in 157 bolnikih, ki so prejemali varfarin (1 %).
English: It is not intended to provide practical advice on how to use Lixiana.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: For practical information about using Lixiana, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Lixiana naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: A first systemic embolism or stroke occurred in 182 patients given standard doses of Lixiana and in 232 of those given warfarin, corresponding to annual rates for these events of around 1.2% and 1.5% respectively.
Slovenian: Prvi pojav sistemske embolije ali možganske kapi so zabeležili pri 182 bolnikih, ki so prejemali standardne odmerke zdravila Lixiana, in 232 bolnikih, ki so prejemali varfarin, kar pomeni, da je bil letni delež teh dogodkov približno 1,2 % oziroma 1,5 %.
English: Dose adjustments may also need to be made in patients who are switched between Lixiana and other anticoagulant medicines.
Slovenian: Odmerek je včasih treba prilagoditi tudi pri bolnikih, ki preidejo na zdravilo Lixiana z drugih antikoagulantov in obratno.
English: By blocking factor Xa, the medicine reduces the levels of thrombin in the blood, which helps treat clots and reduce the risk of them forming in the arteries and veins and leading to DVT, pulmonary embolism, stroke or other organ damage.
Slovenian: Zdravilo Lixiana z zaviranjem faktorja Xa zniža ravni trombina v krvi, s čimer pomaga odpraviti strdke in zmanjša tveganje, da bi se ti tvorili v arterijah in venah ter povzročili globoko vensko trombozo, pljučno embolijo, možgansko kap ali poškodbo drugih organov.
English: For the full list of all side effects reported with Lixiana, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Lixiana, glejte navodilo za uporabo.
English: Doses should be halved in patients with moderately or severely reduced kidney function, or low body weight or in those who are also taking certain medicines (known as P-gp inhibitors) that can interfere with the removal of edoxaban from the body.
Slovenian: Bolniki z zmerno ali hudo okvaro delovanja ledvic, bolniki z nizko telesno maso ali tisti, ki sočasno jemljejo nekatera druga zdravila (imenovana zaviralci P-glikoproteina), ki lahko vplivajo na izločanje edoksabana iz telesa, morajo jemati polovične odmerke.
English: The main measure of effectiveness was the number of patients who had another episode of DVT or pulmonary embolism during the study period.
Slovenian: Glavno merilo učinkovitosti je bilo število bolnikov, pri katerih sta se med trajanjem študije ponovno pojavili globoka venska tromboza ali pljučna embolija.
English: There was a trend for better results in patients with reduced kidney function than those whose kidney function was normal.
Slovenian: Izkazalo se je, da so bili rezultati boljši pri bolnikih z okvarjenim delovanjem ledvic kot pri tistih z normalnim delovanjem ledvic.
English: Lixiana contains the active substance edoxaban.
Slovenian: Zdravilo Lixiana vsebuje zdravilno učinkovino edoksaban.
English: The active substance in Lixiana, edoxaban, is a ‘factor Xa inhibitor'.
Slovenian: Zdravilna učinkovina v zdravilu Lixiana, edoksaban, je zaviralec faktorja Xa.
English: However, the trend for its benefits in preventing stroke in atrial fibrillation to be less clear in those patients with high creatinine clearance (good kidney function) was considered to require further study.
Slovenian: Vendar pa je treba dodatno proučiti opažanje, da so njegove koristi pri preprečevanju možganske kapi pri atrijski fibrilaciji manj očitne pri bolnikih z velikim očistkom kreatinina (dobrim delovanjem ledvic).
English: How does Lixiana work?
Slovenian: Kako zdravilo Lixiana deluje?